Bridgefront Capital’s Nektar Therapeutics NKTR Stock Holding History

Bridgefront Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,089	Closed	-$280K	–	569
2021 Q2	$280K	Buy	+1,089	New	+$301K	0.11%	372

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bridgefront Capital's NKTR Position: Q3 2021 in Review

Bridgefront Capital sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 1,089 shares — an estimated $280K sold.

Bridgefront Capital first reported a position in NKTR in Q2 2021 and held it in 1 quarter. The position peaked at $280K in Q2 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Bridgefront Capital reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
Bridgefront Capital sold 1,089 Nektar Therapeutics shares in Q3 2021, an estimated $280K.
Bridgefront Capital first reported a position in Nektar Therapeutics in Q2 2021 and held it in 1 quarter.
Bridgefront Capital's Nektar Therapeutics position peaked at $280K in Q2 2021.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.